Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date

References

• LiuPChengHRobertsTMZhaoJJTargeting the phosphoinositide 3-kinase pathway in cancerNat Rev Drug Discov20098862764419644473
   PubMed Web of Science ®Google Scholar
• EngelmanJALuoJCantleyLCThe evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNat Rev Genet20067860661916847462
   PubMed Web of Science ®Google Scholar
• BaderAGKangSZhaoLVogtPKOncogenic PI3K deregulates transcription and translationNat Rev Cancer200551292192916341083
   PubMed Web of Science ®Google Scholar
• VivancoISawyersCLThe phosphatidylinositol 3-Kinase AKT pathway in human cancerNat Rev Cancer20022748950112094235
   PubMed Web of Science ®Google Scholar
• FrumanDAMeyersRECantleyLCPhosphoinositide kinasesAnnu Rev Biochem1998674815079759495
   PubMed Web of Science ®Google Scholar
• KatsoROkkenhaugKAhmadiKWhiteSTimmsJWaterfieldMDCellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancerAnnu Rev Cell Dev Biol20011761567511687500
   PubMed Web of Science ®Google Scholar
• CarneroABlanco-AparicioCRennerOLinkWLealJFThe PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implicationsCurr Cancer Drug Targets20088318719818473732
   PubMed Web of Science ®Google Scholar
• EngelmanJATargeting PI3K signalling in cancer: opportunities, challenges and limitationsNat Rev Cancer20099855056219629070
   PubMed Web of Science ®Google Scholar
• ChanSTargeting the mammalian target of rapamycin (mTOR): a new approach to treating cancerBr J Cancer20049181420142415365568
   PubMed Web of Science ®Google Scholar
• SarbassovDDGuertinDAAliSMSabatiniDMPhosphorylation and regulation of Akt/PKB by the rictor-mTOR complexScience200530757121098110115718470
   PubMed Web of Science ®Google Scholar
• FeketeMSantiskulvongCEngCDorigoOEffect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cellsAnticancer Res201232244545222287731
   PubMed Web of Science ®Google Scholar
• ShiYChenLLiJPrognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapyTumour Biol201132238139021086091
   PubMedGoogle Scholar
• CardenCPStewartAThavasuPThe association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerMol Cancer Ther20121171609161722556379
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• CardosoFCostaASenkusE3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Ann Oncol201728Suppl 12
   Web of Science ®Google Scholar
• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• MillerTWHennessyBTGonzalez-AnguloAMHyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerJ Clin Invest201012072406241320530877
   PubMed Web of Science ®Google Scholar
• BoschALiZBergamaschiAPI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancerSci Transl Med20157283283ra51
   PubMed Web of Science ®Google Scholar
• SanchezCGMaCXCrowderRJPreclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancerBreast Cancer Res2011132R2121362200
   PubMed Web of Science ®Google Scholar
• GarrettJTArteagaCLResistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implicationsCancer Biol Ther201111979380021307659
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• ChandarlapatySSakrRAGiriDFrequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancerClin Cancer Res201218246784679123092874
   PubMed Web of Science ®Google Scholar
• EstevaFJGuoHZhangSPTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancerAm J Pathol201017741647165620813970
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med201236652052922149876
   PubMed Web of Science ®Google Scholar
• HortobagyiGNChenDPiccartMCorrelative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2J Clin Oncol201634541942626503204
   PubMed Web of Science ®Google Scholar
• JordanNJDutkowskiCMBarrowDImpact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitroBreast Cancer Res2014161R1224457069
   PubMed Web of Science ®Google Scholar
• WolffACLazarAABondarenkoIRandomized Phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerJ Clin Oncol201331219520223233719
   PubMed Web of Science ®Google Scholar
• KropIEMayerIAGanjuVPictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trialLancet Oncol201617681182127155741
   PubMed Web of Science ®Google Scholar
• MairaSMPecchiSHuangAIdentification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorMol Cancer Ther201211231732822188813
   PubMed Web of Science ®Google Scholar
• BrachmannSMKleylein-SohnJGaulisSCharacterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrationsMol Cancer Ther20121181747175722653967
   PubMed Web of Science ®Google Scholar
• RodonJBranaISiuLLPhase I dose-escalation and-expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsInvest New Drugs201432467068124652201
   PubMed Web of Science ®Google Scholar
• LoPiccoloJBlumenthalGMBernsteinWBDennisPATargeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerationsDrug Resist Updat2008111–2325018166498
   PubMed Web of Science ®Google Scholar
• WestKACastilloSSDennisPAActivation of the PI3K/Akt pathway and chemotherapeutic resistanceDrug Resist Updat20025623424812531180
   PubMed Web of Science ®Google Scholar
• MassacesiCDi TomasoEUrbanPPI3K inhibitors as new cancer therapeutics: implications for clinical trial designOnco Targets Ther2016920321026793003
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdOvercoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathwayCancer Chemother Pharmacol201371482984223377372
   PubMed Web of Science ®Google Scholar
• MayerIAAbramsonVGIsakoffSJStand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol201432121202120924663045
   PubMed Web of Science ®Google Scholar
• BaselgaJImSAIwataHBuparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol201718790491628576675
   PubMed Web of Science ®Google Scholar
• MartinMChanADirixLA randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4)Ann Oncol201728231332027803006
   PubMed Web of Science ®Google Scholar
• MillerTWRexerBNGarrettJTArteagaCLMutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancerBreast Cancer Res201113622422114931
   PubMed Web of Science ®Google Scholar
• HurvitzSAAndreFJiangZCombination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialLancet Oncol201516781682926092818
   PubMed Web of Science ®Google Scholar
• AndreFO’ReganROzgurogluMEverolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialLancet Oncol201415658059124742739
   PubMed Web of Science ®Google Scholar
• AndreFHurvitzSFasoloAMolecular Alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3J Clin Oncol201634182115212427091708
   PubMed Web of Science ®Google Scholar
• SwainSMKimSBCortesJPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studyLancet Oncol201314646147123602601
   PubMed Web of Science ®Google Scholar
• BaselgaJCortesJImSABiomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancerJ Clin Oncol201432333753376125332247
   PubMed Web of Science ®Google Scholar
• SauraCBendellJJerusalemGPhase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapyClin Cancer Res20142071935194524470511
   PubMed Web of Science ®Google Scholar
• LoiblSde la PenaLNekljudovaVNeoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: a randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)Eur J Cancer20178513314528923573
   PubMed Web of Science ®Google Scholar
• GuerinMRezaiKIsambertNPIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancerEur J Cancer201786283628950146
   PubMed Web of Science ®Google Scholar